Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 2/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31106990 | 0.86 | CNR2 (0.44) | CNR2PIK3CAMAP3K12ADORA1SYK | |
| SCHEMBL24955685 | 0.77 | CNR2 (0.37) | CNR2PIK3CAMAP3K12ADORA1SYK | |
| SCHEMBL31106949 | 0.72 | CDK1 (0.43) | ADORA1 | |
| SCHEMBL24954144 | 0.72 | CDK1 (0.43) | ADORA1 | |
| SCHEMBL24956773 | 0.63 | HRH1 (0.35) | MAP3K12CHRM4 | |
| SCHEMBL24956778 | 0.62 | HRH1 (0.38) | CNR2PIK3CAMAP3K12CHRM4 | |
| SCHEMBL31014947 | 0.61 | DYRK1A (0.32) | CNR2 | |
| SCHEMBL13828313 | 0.59 | PIK3CA (0.60) | PIK3CAADORA1 | |
| SCHEMBL13828332 | 0.59 | PIK3CA (0.71) | PIK3CAADORA1 | |
| SCHEMBL24955551 | 0.59 | PIK3CA (0.60) | PIK3CAADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343729-A1 | IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE | Benevolentai Cambridge Limited (GB) | 2024-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343729-A1 | IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE | SI, SLC10A2, NOS3 | CNR2 1522/4885PIK3CA 2011/4885MAP3K12 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.